AbCellera Biologics Inc (ABCL)
3.645
-0.14
(-3.57%)
USD |
NASDAQ |
May 17, 16:00
3.645
0.00 (0.00%)
After-Hours: 20:00
AbCellera Biologics Enterprise Value: 372.34M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 372.34M |
| May 16, 2024 | 413.50M |
| May 15, 2024 | 389.98M |
| May 14, 2024 | 425.26M |
| May 13, 2024 | 434.09M |
| May 10, 2024 | 428.21M |
| May 09, 2024 | 463.49M |
| May 08, 2024 | 431.15M |
| May 07, 2024 | 489.96M |
| May 06, 2024 | 510.54M |
| May 03, 2024 | 487.02M |
| May 02, 2024 | 434.09M |
| May 01, 2024 | 413.50M |
| April 30, 2024 | 413.00M |
| April 29, 2024 | 430.64M |
| April 26, 2024 | 407.12M |
| April 25, 2024 | 368.91M |
| April 24, 2024 | 448.27M |
| April 23, 2024 | 468.84M |
| April 22, 2024 | 480.60M |
| April 19, 2024 | 439.45M |
| April 18, 2024 | 451.21M |
| April 17, 2024 | 454.15M |
| April 16, 2024 | 492.36M |
| April 15, 2024 | 530.57M |
| Date | Value |
|---|---|
| April 12, 2024 | 576.32M |
| April 11, 2024 | 588.06M |
| April 10, 2024 | 611.55M |
| April 09, 2024 | 690.83M |
| April 08, 2024 | 620.36M |
| April 05, 2024 | 576.32M |
| April 04, 2024 | 593.94M |
| April 03, 2024 | 588.06M |
| April 02, 2024 | 570.45M |
| April 01, 2024 | 605.68M |
| March 31, 2024 | 632.08M |
| March 28, 2024 | 565.72M |
| March 27, 2024 | 554.01M |
| March 26, 2024 | 495.45M |
| March 25, 2024 | 580.36M |
| March 22, 2024 | 583.29M |
| March 21, 2024 | 618.42M |
| March 20, 2024 | 624.27M |
| March 19, 2024 | 586.21M |
| March 18, 2024 | 583.29M |
| March 15, 2024 | 618.42M |
| March 14, 2024 | 615.49M |
| March 13, 2024 | 676.98M |
| March 12, 2024 | 668.19M |
| March 11, 2024 | 691.61M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
347.19M
Minimum
Oct 27 2023
15.55B
Maximum
Dec 11 2020
2.948B
Average
1.957B
Median
Jul 18 2022
Enterprise Value Benchmarks
| Acasti Pharma Inc | 0.1704M |
| Aurinia Pharmaceuticals Inc | 473.30M |
| Edesa Biotech Inc | 11.83M |
| Lexaria Bioscience Corp | 35.42M |
| InMed Pharmaceuticals Inc | -5.814M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -40.61M |
| Revenue (Quarterly) | 9.954M |
| Total Expenses (Quarterly) | 61.57M |
| EPS Diluted (Quarterly) | -0.14 |
| Profit Margin (Quarterly) | -408.0% |
| Earnings Yield | -14.29% |
| Normalized Earnings Yield | -14.29 |